Industry

Remedy Robotics 融资 6200 万美元,推进远程血管内卒中手术机器人走向 FDA 审批

Remedy Robotics Raises $62M to Advance Remote Endovascular Stroke Robotics Toward FDA Approval

Why we picked it

卒中救治分秒必争,但会做介入手术的医生大多在大城市。Remedy Robotics 拿了 DCVC 领投的 6200 万美元,做的 N1 系统让医生远程给基层医院患者做取栓手术,手里还有 48 项专利。做医疗机器人或者远程医疗的从业者应该看看。

Remedy Robotics 完成 6200 万美元 B 轮融资,由 DCVC 领投,资金用于推动其 N1 血管内卒中手术机器人系统完成 FDA 审批流程。该公司围绕机器学习与手术机器人方向持有 48 项已授权专利。

Image · HIT Consultant
Body

N1 系统的核心思路是把介入专科医生的判断与床旁操作解耦:医生无需在卒中患者床边,即可通过精密导管驱动硬件远程执行取栓等血管内手术。系统同时整合 AI 软件套件与术前仿真功能,属于典型将物理 AI 应用于手术场景的设备。

卒中救治对时间极度敏感,而能做血管内介入的专科医生高度集中在大医院,偏远地区患者常因转运耗时错过治疗窗口。若 N1 通过 FDA 审批,远程介入有望把顶尖卒中中心的能力延伸到基层医院,这类远程手术机器人也可能改变介入科的资源分布格局。

Original · HIT Consultant

Remedy Robotics Raises $62M to Advance Remote Endovascular Stroke Robotics Toward FDA Approval

What You Should Know The N1 Platform: Physical AI, Preoperative Simulation, and Remote Endovascular Execution Backed by 48 issued patents spanning machine learning and surgical robotics, Remedy Robotics engineered the N1 System to decouple specialist expertise from physical bedside presence. The platform integrates precision catheter-driving hardware with an artificial intelligence software suite capable of supporting ... Read More

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include Remedy Robotics, surgical robots, FDA, funding.

Source attribution: curated from HIT Consultant (@Fred Pennic).